Morphic to present at td cowen 43rd annual health care conference

Waltham, mass., march 03, 2023 (globe newswire) -- morphic therapeutic (nasdaq: morf), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the td cowen 43rd annual health care conference.
MORF Ratings Summary
MORF Quant Ranking